ATE447009T1 - Verfahren zur herstellung angereicherter hämatopoietischer zusammensetzungen, dadurch hergestellte zusammensetzungen sowie deren verwendungen - Google Patents

Verfahren zur herstellung angereicherter hämatopoietischer zusammensetzungen, dadurch hergestellte zusammensetzungen sowie deren verwendungen

Info

Publication number
ATE447009T1
ATE447009T1 AT95935547T AT95935547T ATE447009T1 AT E447009 T1 ATE447009 T1 AT E447009T1 AT 95935547 T AT95935547 T AT 95935547T AT 95935547 T AT95935547 T AT 95935547T AT E447009 T1 ATE447009 T1 AT E447009T1
Authority
AT
Austria
Prior art keywords
compositions
produced therefrom
stem cells
cells
producing enriched
Prior art date
Application number
AT95935547T
Other languages
English (en)
Inventor
Beth L Hill
Benjamin P Chen
Paul J Simmons
Original Assignee
Novartis Ag
Hanson Ct For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Hanson Ct For Cancer Res filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE447009T1 publication Critical patent/ATE447009T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95935547T 1994-11-14 1995-11-13 Verfahren zur herstellung angereicherter hämatopoietischer zusammensetzungen, dadurch hergestellte zusammensetzungen sowie deren verwendungen ATE447009T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/340,047 US5677136A (en) 1994-11-14 1994-11-14 Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
PCT/IB1995/001003 WO1996015229A1 (en) 1994-11-14 1995-11-13 Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE447009T1 true ATE447009T1 (de) 2009-11-15

Family

ID=23331648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95935547T ATE447009T1 (de) 1994-11-14 1995-11-13 Verfahren zur herstellung angereicherter hämatopoietischer zusammensetzungen, dadurch hergestellte zusammensetzungen sowie deren verwendungen

Country Status (8)

Country Link
US (1) US5677136A (de)
EP (1) EP0787181B1 (de)
JP (1) JP3779323B2 (de)
AT (1) ATE447009T1 (de)
AU (1) AU3752795A (de)
CA (1) CA2203525A1 (de)
DE (1) DE69536014D1 (de)
WO (1) WO1996015229A1 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768081B2 (en) * 1996-04-03 2003-12-04 Wellstat Therapeutics Corporation Inhibitor and stimulator of stem cell proliferation and uses thereof
AU3440797A (en) * 1996-07-01 1998-01-21 Novartis Ag Process of obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein
WO1998021334A2 (en) * 1996-11-13 1998-05-22 Morphogenesis, Inc. Antibody mg1 recognizing a small subset of human hematopoietic cells
AU731937B2 (en) * 1996-12-10 2001-04-05 Hadasit Medical Research Services & Development Company Ltd Serum-derived factor inducing cell differentiation and medical uses thereof
EP0848012A1 (de) * 1996-12-13 1998-06-17 Roche Diagnostics GmbH Verwendung von Polypeptiden zur Behandlung von Thrombozytopenien
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
EP0973873B1 (de) * 1997-04-08 2006-06-07 Pall Corporation Verfahren zur gewinnung von seltenen zellen aus blutprodukten
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
WO2001011011A2 (en) 1999-08-05 2001-02-15 Mcl Llc Multipotent adult stem cells and methods for isolation
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
US7129326B2 (en) * 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
US20020098524A1 (en) * 2000-04-14 2002-07-25 Murray Christopher J. Methods for selective targeting
US6828145B2 (en) 2000-05-10 2004-12-07 Cedars-Sinai Medical Center Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
US20030068792A1 (en) * 2000-12-14 2003-04-10 Yiyou Chen Targeted enzymes
US20030147874A1 (en) * 2000-12-14 2003-08-07 Volker Schellenberger Targeted enzyme prodrug therapy
US20080248544A1 (en) * 2000-12-14 2008-10-09 Murray Christopher J Methods And Compositions For Grafting Functional Loops Into A Protein
WO2002093172A1 (en) * 2001-05-17 2002-11-21 Miltenyi Biotec Gmbh Antigen binding fragments for dendritic cell subset and use thereof
US7129034B2 (en) * 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
EP1442115B9 (de) * 2001-11-15 2009-12-16 Children's Medical Center Corporation Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon
ATE464373T1 (de) * 2001-12-21 2010-04-15 Mount Sinai Hospital Corp Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DK1512015T3 (da) 2002-06-12 2009-07-06 Genencor Int Fremgangsmåder til forbedring af bindingsegenskaber hos et molekyle
US20110158966A1 (en) * 2002-07-23 2011-06-30 Judith Seligman Stem cells characterized by expression of germline specific genes
CA2493768A1 (en) * 2002-07-23 2004-01-29 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
WO2007116408A2 (en) * 2006-04-11 2007-10-18 Nanodiagnostics Israel Ltd. Pluripotent stem cells characterized by expression of germline specific genes
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
WO2005098049A2 (en) * 2004-03-25 2005-10-20 California Institute Of Technology Hybridization chain reaction
JP2007536936A (ja) 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 幹細胞集団および使用方法
US20080233100A1 (en) * 2004-06-30 2008-09-25 Yiyou Chen Targeted enzymes
EP1781775B1 (de) * 2004-07-28 2013-05-01 Universite Paris Descartes Vaskuläre stammzellen und deren verwendungen
ATE452987T1 (de) * 2004-09-10 2010-01-15 Genencor Int Verfahren zur erkennung von zielen
US20110098184A1 (en) * 2004-10-15 2011-04-28 Day Anthony G Competitve differntial screeing
CN101048426A (zh) * 2004-10-22 2007-10-03 金克克国际有限公司 分离人抗体
WO2006052991A2 (en) 2004-11-11 2006-05-18 The General Hosptial Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US20080044400A1 (en) * 2004-12-09 2008-02-21 Volker Schellenberger Targeted enzyme prodrug therapy
US7727721B2 (en) 2005-03-08 2010-06-01 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
CA2617611A1 (en) * 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
EP1931806B1 (de) 2005-10-07 2011-10-05 California Institute Of Technology Pkr-aktivierung mittels hybridisierungskettenreaktion
JP5649786B2 (ja) 2006-03-07 2015-01-07 ギータ シュロフ ヒト胚性幹細胞およびそれらの誘導体を含む組成物、使用方法、ならびに調製方法
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
EP2115460A4 (de) 2007-01-18 2010-01-13 Suomen Punainen Risti Veripalv Neues kohlenhydrat aus menschlichen zellen und verfahren zur analyse und modifikation davon
EP2108043A4 (de) 2007-01-18 2010-04-21 Suomen Punainen Risti Veripalv Neue verfahren und reagentien zur produktion von zellen
WO2008106658A2 (en) * 2007-03-01 2008-09-04 California Institute Of Technology TRIGGERED RNAi
EP2607477B1 (de) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotente stammzellen und ihre verwendung
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
WO2008144562A1 (en) 2007-05-16 2008-11-27 California Institute Of Technology A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
US8497364B2 (en) * 2008-02-27 2013-07-30 California Institute Of Technology Triggered RNAi
US20100021904A1 (en) * 2008-05-21 2010-01-28 Pierce Niles A Shielded cross-linking probes
US8241854B2 (en) * 2008-05-22 2012-08-14 California Institute Of Technology Triggered RNAi
US20100021901A1 (en) * 2008-05-22 2010-01-28 Peng Yin Compositions and methods for detecting analytes
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES2657737T3 (es) 2009-07-15 2018-03-06 Calimmune Inc. Vector dual para la inhibición del virus de la inmunodeficiencia humana
WO2011011500A1 (en) 2009-07-21 2011-01-27 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
US20110268810A1 (en) 2009-11-02 2011-11-03 Yale University Polymeric materials loaded with mutagenic and recombinagenic nucleic acids
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
DK2539436T3 (da) 2010-02-25 2021-10-18 Abt Holding Co Modulering af makrofagaktivering
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US8658780B2 (en) 2010-05-18 2014-02-25 California Institute Of Technology Triggered covalent probes for imaging and silencing genetic expression
EP2582793B1 (de) 2010-06-15 2017-09-06 Cellular Dynamics International, Inc. Kompendium aus fertig gebauten stammzellmodellen zur abfrage biologischer reaktionen
WO2012006440A2 (en) 2010-07-07 2012-01-12 Cellular Dynamics International, Inc. Endothelial cell production by programming
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
US8962241B2 (en) 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
US8877438B2 (en) 2010-07-20 2014-11-04 California Institute Of Technology Self-assembled polynucleotide structure
ES2654994T3 (es) 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
CA2826386C (en) 2011-02-08 2020-04-28 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
PL2718416T3 (pl) 2011-06-06 2020-05-18 ReGenesys BVBA Namnażanie komórek macierzystych w bioreaktorach włóknisto-kapilarnych
KR20150029756A (ko) 2011-06-10 2015-03-18 블루버드 바이오, 인코포레이티드. 부신백질이영양증 및 부신척수신경병증을 위한 유전자 요법 벡터
EP2739735A2 (de) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
KR101931403B1 (ko) 2011-09-23 2018-12-21 블루버드 바이오, 인코포레이티드. 개선된 유전자 치료 방법
ES2769270T3 (es) 2011-09-30 2020-06-25 Bluebird Bio Inc Compuestos para transducción viral mejorada
EP2785350B1 (de) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Verbesserte verfahren zur behandlung von ischämie
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
CN109554350B (zh) 2012-11-27 2022-09-23 儿童医疗中心有限公司 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
CN105229144A (zh) 2013-02-22 2016-01-06 细胞动力学国际有限公司 通过组合的遗传工程和化学工程经由正向编程产生肝细胞
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
AU2014248167B2 (en) 2013-04-03 2019-10-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
AU2014266935B2 (en) 2013-04-30 2020-06-11 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
MX375592B (es) 2014-04-25 2025-03-06 The Children´S Medical Center Corp Composiciones y su uso para tratar hemoglobinopatias.
ES2966886T3 (es) 2014-05-09 2024-04-24 Univ Yale Partículas recubiertas con poliglicerol hiperramificado y métodos de elaboración y uso de las mismas
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
US20180112180A1 (en) 2015-01-26 2018-04-26 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US11572543B2 (en) 2015-05-08 2023-02-07 The Children's Medical Center. Corporation Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
US20180214487A1 (en) 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
IL261002B2 (en) 2016-02-12 2024-07-01 Bluebird Bio Inc Vcn enhancer compositions and methods of using the same
US20200308590A1 (en) 2016-02-16 2020-10-01 Yale University Compositions and methods for treatment of cystic fibrosis
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
IL290679B2 (en) 2016-07-05 2023-10-01 California Inst Of Techn Hybridization chain reaction based on a minimal initiator
CA3034617A1 (en) 2016-08-30 2018-03-08 California Institute Of Technology Immunohistochemistry via hybridization chain reaction
EP3548035A4 (de) 2016-11-30 2020-07-22 Case Western Reserve University Kombinationen von 15-pgdh-inhibitoren mit corticosteroiden und/oder tnf-inhibitoren und verwendungen davon
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
EP3583203B1 (de) 2017-02-15 2023-11-01 2seventy bio, Inc. Spenderreparaturtemplates für multiplex-genomeditierung
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
AU2018261637A1 (en) 2017-05-03 2019-12-12 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells.
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
WO2019213273A1 (en) 2018-05-01 2019-11-07 The Children's Medical Center Corporation Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9
WO2019213013A1 (en) 2018-05-02 2019-11-07 The Children's Medical Center Corporation Improved bcl11a micrornas for treating hemoglobinopathies
CA3111186A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
EP3844287B1 (de) 2018-08-31 2024-05-22 Yale University Zusammensetzungen und verfahren zur verbesserung der oligonukleotidbasierten geneditierung
JP7658579B2 (ja) 2018-10-19 2025-04-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 操作された長鎖散在反復エレメント（ｌｉｎｅ）トランスポゾンおよびそれらの使用方法
JP2022513082A (ja) 2018-11-19 2022-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
EP3983542A2 (de) 2019-06-17 2022-04-20 CRISPR Therapeutics AG Verfahren und zusammensetzungen für verbesserte homologie-gerichtete reparatur
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2021013669A1 (en) * 2019-07-24 2021-01-28 Miltenyi Biotec B.V. & Co. KG Assay for identifing colony-forming cells
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2021275122A1 (en) 2020-05-20 2022-12-15 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CN116529266A (zh) 2020-08-31 2023-08-01 耶鲁大学 用于将核酸递送到细胞的组合物和方法
WO2022133246A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2022164796A1 (en) 2021-01-26 2022-08-04 California Institute Of Technology Allosteric conditional guide rnas for cell-selective regulation of crispr/cas
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
US20240279687A1 (en) 2021-06-07 2024-08-22 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
CA3262625A1 (en) 2022-07-22 2024-01-25 The Johns Hopkins University ADMINISTRATION OF TARGETED INTRACELLULAR CRISPR/CAS SYSTEM ACTIVATED BY DENDRIMER AND GENE EDITING
EP4602078A2 (de) 2022-10-11 2025-08-20 Yale University Zusammensetzungen und verfahren zur verwendung zellpenetrierender antikörper
JP2025540052A (ja) 2022-12-01 2025-12-11 イェール ユニバーシティー 細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5147784A (en) * 1990-04-12 1992-09-15 Systemix, Inc. T-lymphocyte progenitor cell assay
CA2170357A1 (en) * 1993-08-25 1995-03-02 David Digiusto Method for producing a highly enriched population of hematopoietic stem cells
US5468612A (en) * 1993-11-19 1995-11-21 Cytomed, Inc. 9804 gene and methods of use thereof

Also Published As

Publication number Publication date
EP0787181B1 (de) 2009-10-28
EP0787181A1 (de) 1997-08-06
WO1996015229A1 (en) 1996-05-23
JPH10513341A (ja) 1998-12-22
CA2203525A1 (en) 1996-05-23
DE69536014D1 (de) 2009-12-10
JP3779323B2 (ja) 2006-05-24
AU3752795A (en) 1996-06-06
US5677136A (en) 1997-10-14

Similar Documents

Publication Publication Date Title
ATE447009T1 (de) Verfahren zur herstellung angereicherter hämatopoietischer zusammensetzungen, dadurch hergestellte zusammensetzungen sowie deren verwendungen
DE69412831D1 (de) Fluorierte bis-ether und verfahren zur ihrer herstellung sowie von fluorierten methylethern
DK0615545T3 (da) Lysater hidrørende fra keratinocytter til brug som sårhelingsmidler
ATE12255T1 (de) Verfahren zur herstellung von selbstreproduzierenden pankreatischen inseln aehnlichen strukturen von saeugetieren.
DE3863463D1 (de) Wasserabweisende faellungskieselsaeure, verfahren zu ihrer herstellung und deren anwendung zur verstaerkung von silikon-elastomeren.
AU641488B2 (en) Human hematopoietic stem cell
ATE13198T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellenantigen, antikoerper und verfahren.
DE69429531D1 (de) Elektrolytische zelle zur herstellung eines oxidierenden gasgemisches
DE69521794D1 (de) Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
EP0763057A4 (de) Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
SE8302654D0 (sv) A method for producing ethanol from xylose-containing substance
ATE5592T1 (de) Verfahren zur herstellung von 4'deoxydaunorubicin und 4'-deoxydoxorubicin, sowie 4'-epi-4'-trifluormethyl-sulfonyloxy-ntrifluoracetyldaunorubicin.
ATE330003T1 (de) Rekombinanter stabiler zellklon, seine herstellung und verwendung
DE3671907D1 (de) Polyolefinschaumzusammensetzungen mit verbesserter raeumlicher stabilitaet unter verwendung bestimmter ungesaettigter stickstoffhaltiger verbindungen sowie verfahren zur herstellung.
AU2158295A (en) Population of cells enriched for myeloid and/or lymphoid progenitors and methods of making and using
Vossen What do we do with irregular correspondences? The case of the Khoe languages
ATA412780A (de) Verfahren zur herstellung neuer 10-halogen-14-oxo-15-hydroxy-e-homoeburnane (3 alpha,17 alpha) sowie deren epimeren, optisch aktiven antipoden und physiologisch vertraeglichen saeureadditionssalze
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
DE3486168D1 (de) Verfahren zur herstellung von l-glutaminsaeure durch fermentation und dabei zu verwendende mutante mikroorganismen.
ATA207094A (de) Verfahren zur herstellung von xanthangummi durch fermentation
ATE172148T1 (de) Verfahren und vorrichtung zur herstellung eines wabenförmigen kernes für wabenförmige verbundplatten
ATA246983A (de) Verfahren zur herstellung eines aktiven belitzementes sowie anordnung zur durchfuehrung des verfahrens
DE69941849D1 (de) Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen
IT1136191B (it) Procedimento per la preparazione di lievito naturale allo stato granulato fine trasportabile e conservabile nel tempo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties